血滞通胶囊治疗高脂血症临床观察

Clinical Observation on Treatment of Hyperlipidemia with Xuezhitong Capsule

目的:观察血滞通胶囊治疗高脂血症临床疗效及安全性。方法:选择高脂血症80例,随机分为观察组和对照组各40例。对照组采用血脂康胶囊治疗,观察组采用血滞通胶囊治疗,疗程均为4周,比较两组临床疗效、各项指标以及药物不良反应发生情况。结果:治疗后观察组总有效率达87.5%,显著高于对照组的67.5%(P<0.05);TG、HDL-C指标改善水平明显优于对照组(P<0.05);两组均未发生严重不良反应。结论:血滞通胶囊能降低TG、TC、LDL-C水平且能明显降低TG水平,升高HDL-C水平,同时临床安全性较高。

Objective: To observe blood stagnation capsule treatment of hyperlipidemia clinical efficacy and safety.Methods:80 cases of hyperlipidemia were divided into two groupsrandomly,each group has 40 cases.The control grouptook Xuezhikang treatment,the observation group blood stagnation Capsule,The treatment lasted four weeks, comparedtheclinical efficacy, the indicators as well as the incidence of adverse drug reactions with two groups.Results: Aftertreatment, the observation group total effective rate of 87.5%, significantly higher than the 67.5% (P<0.05); TG, HDL-Cindex improved significantly better than the control group (P<0.05); two groups were not serious adverse reactions.Conclusion:Xuezhikangcould reduced blood stagnation TG, TC, LDL-C levels and could lower TG levelssignificantly,increased HDL-C levels, had higher safe.